These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 36343266)

  • 21. A novel carcinogenic PI3Kα mutation suggesting the role of helical domain in transmitting nSH2 regulatory signals to kinase domain.
    Ghalamkari S; Alavi S; Mianesaz H; Khosravian F; Bahreini A; Salehi M
    Life Sci; 2021 Mar; 269():118759. PubMed ID: 33189828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional characterization of PI3K C2 domain mutations detected in breast cancer circulating tumor cells and metastatic cells.
    Smit DJ; Brauer H; Horn S; Yigit G; Haider MT; Pogenberg V; Schumacher U; Pantel K; Jücker M
    Cell Signal; 2024 Sep; 121():111270. PubMed ID: 38909932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biophysical aspect of phosphatidylinositol 3-kinase and role of oncogenic mutants (E542K & E545K).
    Kalsi N; Gopalakrishnan C; Rajendran V; Purohit R
    J Biomol Struct Dyn; 2016 Dec; 34(12):2711-2721. PubMed ID: 26646651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation loop sequences confer substrate specificity to phosphoinositide 3-kinase alpha (PI3Kalpha ). Functions of lipid kinase-deficient PI3Kalpha in signaling.
    Pirola L; Zvelebil MJ; Bulgarelli-Leva G; Van Obberghen E; Waterfield MD; Wymann MP
    J Biol Chem; 2001 Jun; 276(24):21544-54. PubMed ID: 11278889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human tumor mutants in the p110alpha subunit of PI3K.
    Liu Z; Roberts TM
    Cell Cycle; 2006 Apr; 5(7):675-7. PubMed ID: 16627990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases.
    Dornan GL; Burke JE
    Front Immunol; 2018; 9():575. PubMed ID: 29616047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cryo-EM structures reveal two allosteric inhibition modes of PI3Kα
    Huang X; Wang K; Han J; Chen X; Wang Z; Wu T; Yu B; Zhao F; Wang X; Li H; Xie Z; Zhu X; Zhong W; Ren X
    Structure; 2024 Jul; 32(7):907-917.e7. PubMed ID: 38582077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Defining How Oncogenic and Developmental Mutations of PIK3R1 Alter the Regulation of Class IA Phosphoinositide 3-Kinases.
    Dornan GL; Stariha JTB; Rathinaswamy MK; Powell CJ; Boulanger MJ; Burke JE
    Structure; 2020 Feb; 28(2):145-156.e5. PubMed ID: 31831213
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation of PI3Kα by physiological effectors and by oncogenic mutations: structural and dynamic effects.
    Gabelli SB; Echeverria I; Alexander M; Duong-Ly KC; Chaves-Moreira D; Brower ET; Vogelstein B; Amzel LM
    Biophys Rev; 2014 Mar; 6(1):89-95. PubMed ID: 25309634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing the subcellular distribution of oncogenic phosphoinositide 3-kinase using microinjection into live cells.
    Layton MJ; Rynkiewicz NK; Ivetac I; Horan KA; Mitchell CA; Phillips WA
    Biosci Rep; 2014 Apr; 34(2):. PubMed ID: 27919038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS.
    Zhao L; Vogt PK
    Cell Cycle; 2010 Feb; 9(3):596-600. PubMed ID: 20009532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting the protein-protein interaction between IRS1 and mutant p110α for cancer therapy.
    Hao Y; Zhao S; Wang Z
    Toxicol Pathol; 2014 Jan; 42(1):140-7. PubMed ID: 24178578
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p110α Hot Spot Mutations E545K and H1047R Exert Metabolic Reprogramming Independently of p110α Kinase Activity.
    Chaudhari A; Krumlinde D; Lundqvist A; Akyürek LM; Bandaru S; Skålén K; Ståhlman M; Borén J; Wettergren Y; Ejeskär K; Rotter Sopasakis V
    Mol Cell Biol; 2015 Oct; 35(19):3258-73. PubMed ID: 26169833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.
    Zhao JJ; Liu Z; Wang L; Shin E; Loda MF; Roberts TM
    Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18443-8. PubMed ID: 16339315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Double
    Vasan N; Razavi P; Johnson JL; Shao H; Shah H; Antoine A; Ladewig E; Gorelick A; Lin TY; Toska E; Xu G; Kazmi A; Chang MT; Taylor BS; Dickler MN; Jhaveri K; Chandarlapaty S; Rabadan R; Reznik E; Smith ML; Sebra R; Schimmoller F; Wilson TR; Friedman LS; Cantley LC; Scaltriti M; Baselga J
    Science; 2019 Nov; 366(6466):714-723. PubMed ID: 31699932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Positive and negative regulation of phosphoinositide 3-kinase-dependent signaling pathways by three different gene products of the p85alpha regulatory subunit.
    Ueki K; Algenstaedt P; Mauvais-Jarvis F; Kahn CR
    Mol Cell Biol; 2000 Nov; 20(21):8035-46. PubMed ID: 11027274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms.
    Zhao L; Vogt PK
    Proc Natl Acad Sci U S A; 2008 Feb; 105(7):2652-7. PubMed ID: 18268322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
    Horn S; Bergholz U; Jücker M; McCubrey JA; Trümper L; Stocking C; Bäsecke J
    Oncogene; 2008 Jul; 27(29):4096-106. PubMed ID: 18317450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insights into the pathological mechanisms of p85α mutations using a yeast-based phosphatidylinositol 3-kinase model.
    Oliver MD; Fernández-Acero T; Luna S; Rodríguez-Escudero I; Molina M; Pulido R; Cid VJ
    Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28143957
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer-specific mutations in PIK3CA are oncogenic in vivo.
    Bader AG; Kang S; Vogt PK
    Proc Natl Acad Sci U S A; 2006 Jan; 103(5):1475-9. PubMed ID: 16432179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.